رجوع
9
17
نطاق اليوم
KWD 11.37
KWD 11.57
نطاق 52 أسبوعًا
KWD 7.67
KWD 12.84
حجم التداول
438,220
متوسط 50 يوم / 200 يوم
KWD 11.63
/
KWD 11.51
الإغلاق السابق
KWD 11.49
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Financial Services (854 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 1.6 | 10.3 |
| P/B | 0.1 | 1.1 |
| ROE % | 4.7 | 11.6 |
| Net Margin % | 18.3 | 16.8 |
| Rev Growth 5Y % | -5.8 | 11.6 |
| D/E | 0.0 | 0.5 |
السعر المستهدف للمحللين
Hold
KWD 10.000
-12.7%
مكرر الربحية المستقبلي
1.1
ربحية السهم المستقبلية
KWD 10.866
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
2.7 B
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
KWD 11.749
KWD 11.411 – KWD 12.110
|
2.9 B | 1 |
| FY2026 |
KWD 10.866
KWD 10.554 – KWD 11.200
|
2.7 B | 2 |
Insider Trading Activity
Buy ratio (90d)
0.0%
19 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 18, 2026 |
Berkowitz Noah
Chief Medical Officer
|
sell | 6,435 | KWD 11.100 | KWD 71,431 |
| Mar 16, 2026 |
MacGregor Bannor Michael
CEO
|
sell | 500,000 | KWD 0.050 | KWD 25,000 |
| Feb 26, 2026 |
Berkowitz Noah
Chief Medical Officer
|
grant | 112,000 | — | — |
| Feb 17, 2026 |
Stayton Noah Edward
EVP, Chief Information Officer
|
grant | 2,935 | — | — |
| Feb 13, 2026 |
Berkowitz Noah
Chief Medical Officer
|
sell | 5,685 | KWD 11.890 | KWD 67,595 |
| Jan 23, 2026 |
Clauser Noah
Chief Financial Officer
|
sell | 317,500 | — | — |
| Jan 2, 2026 |
Glass Noah H.
Director
|
grant | 26,143 | — | — |
| Dec 29, 2025 |
MacGregor Bannor Michael
CEO
|
sell | 1,768,555 | KWD 0.100 | KWD 232,830 |
| Oct 23, 2025 |
Popp Noah Nathaniel
EVP, GC and Secretary
|
grant | 3,240 | — | — |
| Sep 15, 2025 |
Popp Noah Nathaniel
EVP, GC and Secretary
|
grant | 2,589 | KWD 42.490 | KWD 110,007 |
| Aug 21, 2025 |
Stayton Noah Edward
EVP, Chief Information Officer
|
grant | 11,078 | — | — |
| Jun 19, 2025 |
Elbogen Noah A.
|
grant | 2,747 | KWD 45.520 | KWD 125,043 |
| Jun 10, 2025 |
Beren Noah
Director
|
grant | 2,985 | — | — |
| May 31, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
other | 1,855 | KWD 10.500 | KWD 19,478 |
| May 9, 2025 |
Berkowitz Noah
Chief Medical Officer
|
grant | 150,600 | — | — |
| Apr 15, 2025 |
Glass Noah H.
Director
|
grant | 9,933 | — | — |
| Mar 31, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
other | 1,911 | — | — |
| Mar 31, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
grant | 25,000 | — | — |
| Mar 29, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
other | 2,017 | — | — |
النقاط الرئيسية
Revenue declined -5.82% annually over 5 years
Earnings declined -52.90% over the past year
ROE of 4.69% is below average
Net margin of 18.28% shows strong profitability
Debt/Equity of 0.01 — conservative balance sheet
Generating 305.16M in free cash flow
النمو
Revenue Growth (5Y)
-5.82%
Revenue (1Y)-21.06%
Earnings (1Y)-52.90%
FCF Growth (3Y)-26.84%
الجودة
Return on Equity
4.69%
ROIC4.72%
Net Margin18.28%
Op. Margin24.37%
الأمان
Debt / Equity
0.01
Current Ratio4.53
Interest Coverage0.00
التقييم
P/E Ratio
1.61
P/B Ratio0.08
EV/EBITDA-4.61
Dividend Yield0.84%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -21.06% | Revenue Growth (3Y) | -8.41% |
| Earnings Growth (1Y) | -52.90% | Earnings Growth (3Y) | -30.23% |
| Revenue Growth (5Y) | -5.82% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 2.60B | Net Income (TTM) | 475.45M |
| ROE | 4.69% | ROA | 4.04% |
| Gross Margin | 48.12% | Operating Margin | 24.37% |
| Net Margin | 18.28% | Free Cash Flow (TTM) | 305.16M |
| ROIC | 4.72% | FCF Growth (3Y) | -26.84% |
| Safety | |||
| Debt / Equity | 0.01 | Current Ratio | 4.53 |
| Interest Coverage | 0.00 | Dividend Yield | 0.84% |
| Valuation | |||
| P/E Ratio | 1.61 | P/B Ratio | 0.08 |
| P/S Ratio | 0.29 | PEG Ratio | -0.05 |
| EV/EBITDA | -4.61 | Dividend Yield | 0.84% |
| Market Cap | 764.27M | Enterprise Value | -2.92B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 2.60B | 3.29B | 3.10B | 4.29B | 3.31B |
| Net Income | 475.45M | 1.01B | 976.57M | 1.31B | -745.23M |
| EPS (Diluted) | 33.75 | 72.65 | 71.40 | 97.25 | -60.05 |
| Gross Profit | 1.25B | 1.84B | 1.66B | 2.12B | 2.61B |
| Operating Income | 633.89M | 1.10B | 1.09B | 1.20B | 1.26B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 11.78B | 12.69B | 11.80B | 10.89B | 9.40B |
| Total Liabilities | 1.77B | 2.26B | 2.30B | 2.75B | 2.12B |
| Shareholders' Equity | 9.95B | 10.31B | 9.41B | 8.04B | 7.19B |
| Total Debt | 135.99M | 327.06M | 177.99M | 222.24M | 280.86M |
| Cash & Equivalents | 3.82B | 5.19B | 4.40B | 3.40B | 5.01B |
| Current Assets | 6.47B | 7.12B | 6.32B | 5.52B | 6.70B |
| Current Liabilities | 1.43B | 1.89B | 1.90B | 2.28B | 1.88B |
درجات الاستراتيجيات
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#802 of 825
#504 of 710
النشاط الأخير
دخل
Deep Value Investing (Seth Klarman)
Mar 24, 2026
دخل
Defensive Investing (Benjamin Graham)
Mar 24, 2026